Trabectedin Patent Expiration
Trabectedin was first introduced by Janssen Products Lp
Trabectedin Patents
Given below is the list of patents protecting Trabectedin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Evdi | US12303506 | Trabectedin Composition | Feb 18, 2043 | Apotex |
| Yondelis |
US8895557 (Pediatric) | Pharmaceutical formulations of ecteinascidin compounds | Jul 07, 2028 | Janssen Prods |
| Yondelis | US8895557 | Pharmaceutical formulations of ecteinascidin compounds | Jan 07, 2028 | Janssen Prods |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Trabectedin's patents.
Latest Legal Activities on Trabectedin's Patents
Given below is the list recent legal activities going on the following patents of Trabectedin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 May, 2022 | US8895557 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 01 Jul, 2020 | US8895557 |
| Email Notification Critical
| 01 Jul, 2020 | US8895557 |
| Correspondence Address Change Critical
| 29 Jun, 2020 | US8895557 |
| Email Notification Critical
| 18 Jun, 2020 | US8895557 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 18 Jun, 2020 | US8895557 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 May, 2018 | US8895557 |
| Patent Issue Date Used in PTA Calculation Critical
| 25 Nov, 2014 | US8895557 |
| Recordation of Patent Grant Mailed Critical
| 25 Nov, 2014 | US8895557 |
| Email Notification Critical
| 06 Nov, 2014 | US8895557 |
Trabectedin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Trabectedin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS | M.D. Anderson Cancer Center | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas | M.D. Anderson Cancer Center | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma | Centre Oscar Lambret | NA |
COMPLETED
(Mar 1, 2026)
| PHASE2 |
| Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma | Italian Sarcoma Group | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |
| Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma | Italian Sarcoma Group | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |